HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

17 май 2021 01:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED to Attend Upcoming Investor Conferences

07 май 2021 06:00:00 Источник Nasdaq GlobeNewswire

Change of Company Name

04 май 2021 02:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

03 май 2021 06:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

08 апр 2021 02:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

29 мар 2021 01:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

24 мар 2021 08:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

24 мар 2021 02:00:00 Источник Nasdaq GlobeNewswire

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

04 мар 2021 06:00:02 Источник Nasdaq GlobeNewswire

Chi-Med to Announce 2020 Final Results

03 фев 2021 01:00:00 Источник Nasdaq GlobeNewswire